Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

COVID-19 Vaccination Might Induce Reversible Cerebral Vasoconstriction Syndrome Attacks: A Case Report

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{8c4576edf36c4275a6b84b1e94f09b04,
title = "COVID-19 Vaccination Might Induce Reversible Cerebral Vasoconstriction Syndrome Attacks: A Case Report",
abstract = "A 30-year-old male diagnosed three years previously with reversible cerebral vasoconstriction syndrome (RCVS) presented to the department of neurology with an accumulation of attacks mimicking previous RCVS attacks and fulfilling the diagnostic criteria for RCVS after receiving the first Pfizer COVID-19 vaccine. The neurologic exam, blood samples, electrocardiogram (ECG), and computer tomography of the head (CTC) were normal. The patient was treated with the angiotensin 2 receptor antagonist, losartan, with a good response and was discharged with a prescription for losartan lasting until three days after the second Pfizer COVID-19 vaccine. No further RCVS attacks were reported. These findings indicate that the COVID-19 vaccine might induce RCVS attacks in susceptible individuals, and targeting the angiotensin 2 receptor could be a preventive option.",
keywords = "corona virus, Pfizer, vaccination, headache",
author = "Lund, {Anne Marie} and {Al-Mahdi Al-Karagholi}, Mohammad",
year = "2022",
month = may,
day = "23",
doi = "10.3390/vaccines10050823",
language = "English",
volume = "10",
journal = "Vaccines",
issn = "1554-8600",
publisher = "Landes Bioscience",
number = "5",

}

RIS

TY - JOUR

T1 - COVID-19 Vaccination Might Induce Reversible Cerebral Vasoconstriction Syndrome Attacks

T2 - A Case Report

AU - Lund, Anne Marie

AU - Al-Mahdi Al-Karagholi, Mohammad

PY - 2022/5/23

Y1 - 2022/5/23

N2 - A 30-year-old male diagnosed three years previously with reversible cerebral vasoconstriction syndrome (RCVS) presented to the department of neurology with an accumulation of attacks mimicking previous RCVS attacks and fulfilling the diagnostic criteria for RCVS after receiving the first Pfizer COVID-19 vaccine. The neurologic exam, blood samples, electrocardiogram (ECG), and computer tomography of the head (CTC) were normal. The patient was treated with the angiotensin 2 receptor antagonist, losartan, with a good response and was discharged with a prescription for losartan lasting until three days after the second Pfizer COVID-19 vaccine. No further RCVS attacks were reported. These findings indicate that the COVID-19 vaccine might induce RCVS attacks in susceptible individuals, and targeting the angiotensin 2 receptor could be a preventive option.

AB - A 30-year-old male diagnosed three years previously with reversible cerebral vasoconstriction syndrome (RCVS) presented to the department of neurology with an accumulation of attacks mimicking previous RCVS attacks and fulfilling the diagnostic criteria for RCVS after receiving the first Pfizer COVID-19 vaccine. The neurologic exam, blood samples, electrocardiogram (ECG), and computer tomography of the head (CTC) were normal. The patient was treated with the angiotensin 2 receptor antagonist, losartan, with a good response and was discharged with a prescription for losartan lasting until three days after the second Pfizer COVID-19 vaccine. No further RCVS attacks were reported. These findings indicate that the COVID-19 vaccine might induce RCVS attacks in susceptible individuals, and targeting the angiotensin 2 receptor could be a preventive option.

KW - corona virus

KW - Pfizer

KW - vaccination

KW - headache

UR - http://www.scopus.com/inward/record.url?scp=85131071252&partnerID=8YFLogxK

U2 - 10.3390/vaccines10050823

DO - 10.3390/vaccines10050823

M3 - Journal article

C2 - 35632579

VL - 10

JO - Vaccines

JF - Vaccines

SN - 1554-8600

IS - 5

M1 - 823

ER -

ID: 78297139